Effect of Intradermal Thumbtack Needle for Functional Constipation: Study Protocol for a Real- World Clinical Trial

Wenqian Zhao, Ying Xu, Jing-Jing Liao, Ji Li, Li Wang, Jingkui Cao, Yishi Tang, Jirui Gu, Dehua LiResearch Square 2021 · DOI

TL;DR

This study protocol outlines a large-scale, real-world randomized controlled trial (RCT) designed to test whether "thumbtack" intradermal needles are as effective as standard drug therapy for functional constipation. By leaving tiny needles in the skin for 72 hours, the researchers aim to provide the benefits of continuous acupuncture without the time-intensive clinic visits required by traditional methods.

What Problem Does This Paper Address?

Functional Constipation (FC) is a pervasive gastrointestinal disorder affecting up to 29% of the population in some regions. Beyond the physical discomfort, it is frequently linked to anxiety, depression, and a significant decrease in quality of life.

While traditional acupuncture has been clinically proven to help, it presents a logistical hurdle: patients must visit a clinic frequently for sessions that require them to remain still while needles are inserted. This "time poverty" leads to high dropout rates. The authors are investigating intradermal thumbtack needles—tiny, 1.3mm needles that are taped onto acupoints for days at a time—as a more convenient, "long-acting" alternative to traditional acupuncture and standard prokinetic drugs like Mosapride.

Methods

The study is a multi-center, real-world clinical trial involving 482 patients across three hospitals in China. The "real-world" designation means the inclusion criteria are broader than a typical restrictive RCT, allowing for patients with underlying complications to better reflect actual clinical practice.

  • Group A (Intervention): Patients receive intradermal thumbtack needles (0.22 × 1.3mm) at specific acupoints twice a week. The needles remain in the dermis for 72 hours, providing continuous stimulation.
  • Group B (Control): Patients take Mosapride citrate (a standard drug that enhances gastric motility) three times a day.
  • Duration: 4 weeks of treatment followed by a 4-week follow-up period to check for lasting effects.
  • Randomization: 1:1 ratio using a computer-generated random number table.
  • Blinding: While patients and practitioners cannot be blinded (due to the nature of needles vs. pills), the outcome assessors and statisticians are kept "blind" to group assignments to prevent bias.

Datasets

As this is a clinical trial protocol, the "dataset" consists of the clinical data to be collected from the 482 recruited participants. Evaluation tools include:

  • Primary Outcome: Weekly Completely Spontaneous Bowel Movements (CSBMs).
  • Secondary Outcomes: Stool consistency (Bristol Stool Form Scale), symptom severity (Cleveland Constipation Score), and quality of life (PAC-QOL).
  • Psychological Metrics: Self-rating scales for anxiety (SAS) and depression (SDS).

Key Insights and Ideas

  • Continuous Stimulation: Unlike traditional acupuncture, which lasts about 30 minutes, the thumbtack needle provides 72 hours of continuous "micro-needle" sensation. The authors hypothesize this "lasting effect" may be more potent for regulating the enteric nervous system.
  • Syndrome Differentiation: The protocol blends modern trial design with Traditional Chinese Medicine (TCM) logic. All patients receive stimulation at core points (like Tianshu and Zusanli), but additional points are added based on the patient's specific TCM "syndrome" (e.g., "cold constipation" vs. "qi stagnation").
  • Pragmatic Comparison: Instead of using a placebo (sham acupuncture), the study compares the intervention to a "positive drug" (Mosapride). This provides more actionable data for clinicians deciding between pharmaceutical and physical therapies.

Key Results

As this paper describes the study protocol, final results are not yet available. However, the authors report:

  • Trial Status: The trial was registered in February 2021 and began recruitment in March 2021.
  • Current Progress: At the time of publication, 82 of the target 482 patients had been enrolled.
  • Hypothesis: The researchers expect the intradermal needle group to show efficacy that is "better than or equal to" the drug group, particularly in the follow-up period where acupuncture often shows more sustained results than medication.

Limitations and Future Work

  • Blinding Challenges: The lack of a double-blind design is a noted limitation. Patients' expectations of acupuncture versus medication could influence self-reported scores (the "expectancy effect").
  • Real-World Noise: While real-world designs improve "extrapolation" (how well the results apply to the general public), they also introduce more variables and "noise" than a highly controlled lab-style RCT.
  • Future Directions: If successful, this study could validate a low-cost, minimally invasive treatment that patients can essentially "wear" home, potentially reducing the economic and time burden of chronic constipation management.

Summary updated

Abstract

<title>Abstract</title> <bold>Background: </bold>Many high-quality clinical trials have proved the efficacy of acupuncture in the improving frequency of spontaneous bowel movements, stool characteristics, and et cetera of Functional Constipation (FC) [1]. However, the high requirement of time make many patients unable to attend, this clinical trial will demonstrate the efficacy of intradermal thumbtack needle in ameliorate spontaneous bowel movement of FC.<bold>Methods: </bold>This multi-center real world clinical trial is performed involving 482 FC patients. All patients are randomly allocated into 2 group, which are group A to receive intradermal thumbtack needle twice a week for 4 weeks (intervention group n=241) or group B to take oral administration of mosapride 3 times a day for 4 weeks (control group n=241). This trial includes a 4-week treatment period and a 4-week follow-up period. The primary outcome is the number of completely spontaneous defecation per week, we use Weekly CSBMs analyze the frequency of spontaneous defecation per week during treatment and follow-up period to compared with the baseline. The secondary outcomes include FC patients’ stool consistence, gastrointestinal or anorectal symptoms, quality of life, anxiety and depression levels during treatment and follow-up period and efficacy expectations. The relevant assessment tools include: Bristol tool Form Scale (BSFS), Cleveland Constipation Score (CCS), Patient Assessment of Constipation Quality of Life Questionnaire(PAC-QOL), Self-rating Anxiety Scale (SAS) , Self-rating Depression Scale (SDS) and Efficacy Expectancy Scale. At the end, the scales filled by patients and researchers will be entered by data administrator, all the outcome assessments will be performed by independent outcome assessors and will be analyzed by professional statisticians with SPSS 25.0 software.<bold>Discussion</bold>: We hypothesize that intradermal needle is better than or equal to positive drugs in the improving frequency of spontaneous bowel movements, stool characteristics,and et cetera of FC patients . The results of this trial will provide us with a clinical basis for the application of intradermal needles in the treatment of FC.<bold>Trial registration:</bold> Chinese Clinical Trial Registry, ChinCTR2100043684.Registered on 26 February 2021.
BibTeX
@inproceedings{zhao2021effect,
  author = {Wenqian Zhao and Ying Xu and Jing-Jing Liao and Ji Li and Li Wang and Jingkui Cao and Yishi Tang and Jirui Gu and Dehua Li},
  title = {{Effect of Intradermal Thumbtack Needle for Functional Constipation: Study Protocol for a Real- World Clinical Trial}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-832408/v1},
}
Figure